Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Omar Albanyan, MD, Seongho Kim, PhD, Anupama Kottam, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Dipenkumar Modi, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141416

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Omar Albanyan, MD, Samer Alkassis, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Dipenkumar Modi, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140079

Published: 2020

Journal Articles

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Dipenkumar Modi, MD, Vijendra Singh, MD, Seongho Kim, PhD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2019) 134 (Supplement_1): 4488.

https://doi.org/10.1182/blood-2019-125418

Published: 2019

Journal Articles

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Dipenkumar Modi, MD, Malini Surapaneni, MD, Seongho Kim, PhD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 4527.

https://doi.org/10.1182/blood-2019-125437

Published: 2019

Journal Articles

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Harsh Shah, DO, Paramveer Singh, MD, Jorgena Kosti, DO, Hyejeong Jang, Seongho Kim, PhD, Andrew Kin, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 5702.

https://doi.org/10.1182/blood-2019-124931

Published: 2019

Journal Articles

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Dipenkumar Modi, MD, Seongho Kim, PhD, Jie Chi, MD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 3311.

https://doi.org/10.1182/blood-2019-124838

Published: 2019

Journal Articles

Post-ASCT Outcomes in Multiple Myeloma Patients Who Underwent ASCT with G-CSF+Plerixafor Versus G-CSF Mobilized Graft

Harsh Shah, DO, Seongho Kim, PhD, Paramveer Singh, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2018-99-113713

Published: 2018

Journal Articles

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Nadine Abdallah, MD, Seongho Kim, PhD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2018-99-118400

Published: 2018

Journal Articles

Long-Term Outcomes of Allogeneic Stem Cell Transplant in Peripheral T-Cell Lymphoma

Dipenkumar Modi, MD, Seongho Kim, PhD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2018) 132 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2018-99-114288

Published: 2018

Journal Articles

Long Term Outcomes of Allogeneic Transplant in Diffuse Large B-Cell Lymphoma

Dipenkumar Modi, MD, Seongho Kim, PhD, Malini Surapaneni, MD, Abhinav Deol, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2018) 132 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2018-99-114278

Published: 2018

Journal Articles

Pre-Transplant Hypomethylating Agents Do Not Influence Post-Transplant Outcomes in Myelodysplastic Syndrome

Dipenkumar Modi, MD, Seongho Kim, PhD, Vijendra Singh, MD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 3102.

https://doi.org/10.1182/blood-2018-99-114256

Published: 2018

Journal Articles

Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation

Dipenkumar Modi, MD, Seongho Kim, PhD, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 2034.

https://doi.org/10.1182/blood.V130.Suppl_1.2034.2034

Published: 2017

Journal Articles

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

Naresh Bumma, MD, Monica Peravali, MD, Jayadev Mettu, MD, Ghayathri Jeyakumar, MD, Seongho Kim, PhD, Divaya Bhutani, MD, Abhinav Deol, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Asif Alavi, MD

Blood (2017) 130 (Supplement 1): 5518.

https://doi.org/10.1182/blood.V130.Suppl_1.5518.5518

Published: 2017

Journal Articles

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Dipenkumar Modi, MD, Wei Chen, Hyejeong Jang, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 3275.

https://doi.org/10.1182/blood.V130.Suppl_1.3275.3275

Published: 2017

Journal Articles

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

John M. Timmerman, MD, Andreas Engert, MD, Anas Younes, MD, Armando Santoro, Philippe Armand, MD PhD, Michelle A Fanale, MD, Graham P. Collins, MD PhD, Voravit Ratanatharathorn, MD, John Kuruvilla, MD, Jonathon B. Cohen, MD, Kerry J Savage, MD, Marek Trneny, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Scott J Rodig, Kazunobu Kato, MD, Anne Sumbul, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 1110.

https://doi.org/10.1182/blood.V128.22.1110.1110

Published: 2016

Journal Articles

Age up to 75 Years Does Not Influence the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Dipenkumar Modi, MD, Abhinav Deol, MD, Seongho Kim, PhD, Kendra Mellert, M.S.A.; C.C.R.P., Marie Ventimiglia, Alavi Asif, MD, Divaya Bhutani, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2016) 128 (22): 3501.

https://doi.org/10.1182/blood.V128.22.3501.3501

Published: 2016

Journal Articles

Transfer of Immunity Using Vaccinate and Boost Strategy with Bispecific Antibody Armed T Cells (BATs) in Metastatic Breast Cancer Patients

Archana Thakur, PhD, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Lawrence G. Lum, MD DSC

Blood (2016) 128 (22): 3459.

https://doi.org/10.1182/blood.V128.22.3459.3459

Published: 2016

Journal Articles

A Phase II Study of Tacrolimus and Thymoglobulin, As Graft-Versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Allogeneic Hematopoietic Cell Transplantation

Dipenkumar Modi, MD, Wei Chen, PhD, Jang Hyejeong, Abhinav Deol, MD, Lois Ayash, MD, Alavi Asif, MD, Divaya Bhutani, Kendra Mellert, M.S.A.; C.C.R.P., Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2016) 128 (22): 4579.

https://doi.org/10.1182/blood.V128.22.4579.4579

Published: 2016

Journal Articles

Chromosome 9p24.1/ PD-L1 / PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Blood (2016) 128 (22): 2923.

https://doi.org/10.1182/blood.V128.22.2923.2923

Published: 2016

NARROW

Incidence, Risk Factors and Outcomes of Cardiac Toxicity in Haploidentical Peripheral Stem Cell Transplantation with High Dose Cyclophosphamide

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Impact of Pre-Transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission

Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Relapse-Free and Overall Survival

Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Can Peri-Transplant Radiation Therapy Improve Outcomes of Autologous Stem Cell Transplant in Hodgkin Lymphoma?

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Post-ASCT Outcomes in Multiple Myeloma Patients Who Underwent ASCT with G-CSF+Plerixafor Versus G-CSF Mobilized Graft

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Long-Term Outcomes of Allogeneic Stem Cell Transplant in Peripheral T-Cell Lymphoma

Long Term Outcomes of Allogeneic Transplant in Diffuse Large B-Cell Lymphoma

Pre-Transplant Hypomethylating Agents Do Not Influence Post-Transplant Outcomes in Myelodysplastic Syndrome

Comparison of Outcomes of Post-Transplant Cyclophosphamide between Haplo-Identical and Matched/Mismatched Donor Peripheral Blood Stem Cell Transplantation

Post Autologous Stem Cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/ VGPR after Induction Therapy

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Age up to 75 Years Does Not Influence the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Transfer of Immunity Using Vaccinate and Boost Strategy with Bispecific Antibody Armed T Cells (BATs) in Metastatic Breast Cancer Patients

A Phase II Study of Tacrolimus and Thymoglobulin, As Graft-Versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Allogeneic Hematopoietic Cell Transplantation

Chromosome 9p24.1/ PD-L1 / PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only